Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).

A systematic review of Alzheimer disease (AD) treatments currently in development demonstrate the progressive emphasis on nonamyloid targets, including candidate treatments addressing for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions.

Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer's disease clinical trials, led a five-year review of all Alzheimer's drugs in the development pipeline. He says today there is more hope than ever that we'll one day solve Alzheimer's.

Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer’s disease clinical trials, led a five-year review of all Alzheimer’s drugs in the development pipeline. He says today there is more hope than ever that we'll one day solve Alzheimer’s.

The UNLV Department of Brain Health has formally launched the Chambers-Grundy Center for Transformative Neuroscience, offering hope through scientific discovery for patients suffering from Alzheimer’s, dementia and other brain and neurological diseases. The center is the latest in a series of milestones from the department and the School of Integrated Health Sciences to better understand how a healthy brain functions, to improve care and treatment of people with brain diseases, and to identify mechanisms of brain disorders.

The University of Nevada, Las Vegas has announced a $6 million commitment from Joy Chambers-Grundy and the late Reg Grundy to establish a center dedicated to research on and the treatment of neurological disorders.

The University of Nevada, Las Vegas has announced a $6 million commitment from Joy Chambers-Grundy and the late Reg Grundy to establish a center dedicated to research on and the treatment of neurological disorders.

UNLV announced Monday that it has launched a center dedicated to scientific research about brain and neurological diseases such as Alzheimer’s and dementia.

UNLV announced Monday that it has launched a center dedicated to scientific research about brain and neurological diseases such as Alzheimer’s and dementia.

The UNLV department of brain health has formally launched the Chambers-Grundy Center for Transformative Neuroscience, offering hope through scientific discovery for patients who are suffering from Alzheimer’s, dementia and other brain and neurological diseases.

The UNLV department of brain health has formally launched the Chambers-Grundy Center for Transformative Neuroscience, offering hope through scientific discovery for patients who are suffering from Alzheimer’s, dementia and other brain and neurological diseases.